Dr. Sara Tolaney oversees an independent and diverse scientific review committee composed of experts in oncology who review all applications and select who will receive funding. Diversity is at the forefront of her mind.
Congratulations to Michael Elliott, Vice President of Development and Medical Affairs at Gilead, for being named to this year's Empower Advocate Executive Role Model List.
We’re pleased to announce that we're joining the global Access to Oncology Medicines (ATOM) Coalition to help improve care and access to essential cancer medicines in low- and lower middle-income countries.
“Gilead's support for community organizations is part of our enduring commitment to ending the HIV epidemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
Gilead scientists had planned for a moment like this through years of research. When coronaviruses with pandemic potential, like SARS and MERS, emerged in the early 2000s, Gilead began searching for potential new antivirals.
This Earth Day, we’re highlighting our longstanding commitment to environmental stewardship. We’ll continue to accelerate our efforts to reduce greenhouse gas emissions, minimize waste generation and operate responsibly.
If left untreated, VL kills 95% of its victims. Though progress has been made, we still have a way to go and, as we look to the next decade, eliminating VL will continue to be a priority for Gilead Sciences.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...